266 related articles for article (PubMed ID: 28147223)
1. Current Challenges and Emerging Solutions in Upper GI Disorders: A Brief Report of the 2016 AGA Drug Development Conference.
Howden CW; Vakil NB
Gastroenterology; 2017 Mar; 152(4):e1-e4. PubMed ID: 28147223
[No Abstract] [Full Text] [Related]
2. Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease.
Zatorski H; Mosinska P; Storr M; Fichna J
J Physiol Pharmacol; 2017 Dec; 68(6):797-805. PubMed ID: 29550791
[TBL] [Abstract][Full Text] [Related]
3. Prokinetics and fundic relaxants in upper functional GI disorders.
Tack J
Curr Opin Pharmacol; 2008 Dec; 8(6):690-6. PubMed ID: 18940266
[TBL] [Abstract][Full Text] [Related]
4. Prokinetics in the Management of Functional Gastrointestinal Disorders.
Quigley EMM
Curr Gastroenterol Rep; 2017 Sep; 19(10):53. PubMed ID: 28887755
[TBL] [Abstract][Full Text] [Related]
5. Upper Gastrointestinal Functional and Motility Disorders in Children.
Miller J; Khlevner J; Rodriguez L
Pediatr Clin North Am; 2021 Dec; 68(6):1237-1253. PubMed ID: 34736587
[TBL] [Abstract][Full Text] [Related]
6. American Gastroenterological Association Drug Development Conferences: A Model for Future Collaborations.
Howden CW; Vakil NB
Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1195-1196. PubMed ID: 28300692
[No Abstract] [Full Text] [Related]
7. Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: A Paradigm Shift.
Molina-Infante J; Lucendo AJ
Am J Gastroenterol; 2017 Dec; 112(12):1770-1773. PubMed ID: 29087399
[No Abstract] [Full Text] [Related]
8. Gastrointestinal motility tests--when to call the motility lab?
Quigley EM; Byrne KG
Nebr Med J; 1994 Nov; 79(11):367-71. PubMed ID: 7830840
[No Abstract] [Full Text] [Related]
9. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
10. Functional Dyspepsia - A Revolution in Management.
Oshima T; Miwa H
Am J Gastroenterol; 2018 Oct; 113(10):1420-1422. PubMed ID: 30181534
[No Abstract] [Full Text] [Related]
11. Gastroduodenal motility disorders.
Tack J; Van den Houte K; Carbone F
Curr Opin Gastroenterol; 2018 Nov; 34(6):428-435. PubMed ID: 30199408
[TBL] [Abstract][Full Text] [Related]
12. [Pathomechanisms of functional gastroparesis].
Sobocki J; Królczyk G; Thor PJ
Folia Med Cracov; 2006; 47(1-4):51-9. PubMed ID: 18038612
[TBL] [Abstract][Full Text] [Related]
13. Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.
Katzka DA; Loftus EV; Camilleri M
Clin Pharmacol Ther; 2012 Sep; 92(3):306-20. PubMed ID: 22828717
[TBL] [Abstract][Full Text] [Related]
14. Eosinophilic esophagitis: Update in diagnosis and management. Position paper by the Italian Society of Gastroenterology and Gastrointestinal Endoscopy (SIGE).
de Bortoli N; Penagini R; Savarino E; Marchi S
Dig Liver Dis; 2017 Mar; 49(3):254-260. PubMed ID: 27979389
[TBL] [Abstract][Full Text] [Related]
15. Drugs under development for the treatment of functional dyspepsia and related disorders.
Tack J; Masuy I; Van Den Houte K; Wauters L; Schol J; Vanuytsel T; Vandenberghe A; Carbone F
Expert Opin Investig Drugs; 2019 Oct; 28(10):871-889. PubMed ID: 31566013
[No Abstract] [Full Text] [Related]
16. Upper GI Disorders: Pathophysiology and Current Therapeutic Approaches.
Parkman HP
Handb Exp Pharmacol; 2017; 239():17-37. PubMed ID: 28105529
[TBL] [Abstract][Full Text] [Related]
17. Cisapride: what can we learn from the rise and fall of a prokinetic?
Quigley EM
J Dig Dis; 2011 Jun; 12(3):147-56. PubMed ID: 21615867
[TBL] [Abstract][Full Text] [Related]
18. Meeting Report: AGA Biosimilars Roundtable.
Howden CW; Lichtenstein GR
Gastroenterology; 2018 Apr; 154(5):e1-e5. PubMed ID: 29510132
[No Abstract] [Full Text] [Related]
19. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.
Scheiman JM; Herlitz J; Veldhuyzen van Zanten SJ; Lanas A; Agewall S; Nauclér EC; Svedberg LE; Nagy P
J Cardiovasc Pharmacol; 2013 Mar; 61(3):250-7. PubMed ID: 23188121
[TBL] [Abstract][Full Text] [Related]
20. Frequency scale symptoms for gastroesophageal reflux disease (Frequency Scale for Symptoms of GERD) predicts need for addition of prokinetics to proton pump inhibitor therapy.
Nandurkar S
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1165-7. PubMed ID: 18699977
[No Abstract] [Full Text] [Related]
[Next] [New Search]
